FDA clears surgical system for viscoelastic fluid delivery
Key takeaways:
- The VIA360 surgical system is also indicated for cutting trabecular meshwork tissue during trabeculotomy.
- New World Medical plans to launch the system immediately.
The FDA granted 510(k) clearance for the VIA360 surgical system, which is designed to deliver viscoelastic fluid during ophthalmic surgeries, according to a press release from New World Medical.
“This system features ActiveInject technology, enabling precise viscoelastic delivery independent of catheter movement or device rotation,” Raymond Kong, chief commercial officer at New World Medical, told Healio. “Its single-entry mechanism supports up to 360° catheterization, enhancing precision and control during trabeculotomy procedures.”
VIA360 is designed for stand-alone procedures or in combination with cataract surgery. In addition to viscoelastic delivery, it is indicated to cut trabecular meshwork tissue during trabeculotomy.
The system features a rotatable cannula to provide enhanced positioning and flexibility for targeted delivery without requiring full device rotation, the release said.
New World Medical plans to launch the system immediately in the United States.
“By addressing gaps in current surgical tools, the VIA360 surgical system aims to improve ophthalmic surgery outcomes,” Kong told Healio. “As we introduce this system to the market, we remain dedicated to delivering exceptional value and driving innovation in eye care.”
Collapse
Read more about